Norfolk entrepreneur Tait Pollack from Norwich has credited sleep for saving his life after recovering from a life-threatening illness following ...

AstraZeneca (NASDAQ:AZN ... and label expansions for Tagrisso and Imfinzi in the second half of the previous year. It is equally critical to discuss the successes and failures in the ...

Market focus will remain on earnings from major tech companies, in the wake of the sell-off in artificial ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

WASHINGTON: The Central Intelligence Agency on Saturday shifted its official stance on the origin of COVID-19, saying that it ...

The U.S. government has selected the second batch of drugs up for Medicare ... Bristol Myers Squibb, AstraZeneca, GSK and other companies. Novo’s booming semaglutide franchise for diabetes ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.

AstraZeneca's lengthy and turbulent development ... The CTLA4 inhibitor – now given the brand name Imjudo – is only the second drug in the class to be approved after Bristol-Myers Squibb's ...

Nanexa AB announces that the phase I study with NEX-22, the company's one-month formulation of liraglutide, will resume with further dose escalation with an expected start in the first quarter of 2025 ...